Thyroid tumor
Conditions
Interventions
Con group:ropivacaine was used in cervical nerve pathway blocking
D1 group:dexmedetomidine as an adjuvant to cervical nerve pathway blocking
D2 group:cervical nerve pathway blocking combined with intravenous administration of dexmedetomidine
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients willing to sign informed consent; 2. 18-65 years old; 3. ASA class I-III; 4. Patients who will undergo selective thyroidectomy.
Exclusion criteria
Exclusion criteria: 1. With coagulation dysfunction; 2. Patients with infection at the puncture site; 3. Patients allergic to the study drug; 4. Analgesic drug addicts; 5. Heat rate < 50 beats/minutes or II-III Atrioventricular block; 6. With chronic pain, mental or nervous system disease; 7. With serious disease of heart head blood-vessel, liver and kidney function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| The first time of analgesics added at the ward;Complications such as somnolence, sinus bradycardia, nausea, vomiting, hoarseness, sore throat.; | — |
Countries
China
Contacts
Public ContactYuanhai Li
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed